ReviewCancer immunology, immunotherapy : CII2016
Opportunities for immunotherapy in microsatellite instable colorectal cancer.
Review in Cancer immunology, immunotherapy : CII, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 82 citations in OpenAlex.
- Reduction of circulating lymphocyte count is a predictor of good tumor response after neoadjuvant treatment for rectal cancer.Medicine · 2018Trial
- Efficacy of Radiotherapy Combined with Immunotherapy in MSS/pMMR Metastatic Colorectal Cancer: a Propensity-Matched Retrospective Study.Journal of gastrointestinal cancer · 2025Article
- KCNC3 as a prognostic indicator and a predictive marker for immunotherapy in colorectal cancer.Journal of gastrointestinal oncology · 2025Article
- Case Report: A case of synchronous multiple early gastric cancer with a microsatellite instability-high phenotype.Frontiers in oncology · 2025Article
- Report of the sixth meeting of the European Consortium 'Care for CMMRD' (CFamilial cancer · 2024Article
- High Probability of Lynch Syndrome Among Colorectal Cancer Patients Is Associated With Higher Occurrence of KRAS and PIK3CA Mutations.World journal of oncology · 2024Article
- Deep learning for dual detection of microsatellite instability and POLE mutations in colorectal cancer histopathology.NPJ precision oncology · 2024Article
- Current Trends in Vaccine Development for Hereditary Colorectal Cancer Syndromes.Clinics in colon and rectal surgery · 2024Review
- A case report of sustained remission after radiotherapy combined with ICI in NEPC with primary drug resistance to chemotherapy.Frontiers in oncology · 2024Article
- Serum exosomal hsa-circ-0004771 modulates the resistance of colorectal cancer to 5-fluorouracil via regulating miR-653/ZEB2 signaling pathway.Cancer cell international · 2023Article
- A Novel Mutation ofJournal of clinical medicine · 2023Article
- Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma.Scientific reports · 2023Article
- Can immunotherapy reinforce chemotherapy efficacy? a new perspective on colorectal cancer treatment.Frontiers in immunology · 2023Review
- Association of cigarette smoking with risk of colorectal cancer subtypes classified by gut microbiota.Tobacco induced diseases · 2023Article
- Hereditary Colorectal Cancer Syndromes: Molecular Genetics and Precision Medicine.Biomedicines · 2022Review
- Vaccines for immunoprevention of DNA mismatch repair deficient cancers.Journal for immunotherapy of cancer · 2022Review
- Neoadjuvant immunotherapy in primary and metastatic colorectal cancer.The British journal of surgery · 2021Review
- Prognostic Impact and Functional Annotations of KIF11 and KIF14 Expression in Patients with Colorectal Cancer.International journal of molecular sciences · 2021Article
- DNA alkylation lesion repair: outcomes and implications in cancer chemotherapy.Journal of Zhejiang University. Science. B · 2021Review
- The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer.Frontiers in immunology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Microsatellite instability (MSI), the somatic accumulation of length variations in repetitive DNA sequences called microsatellites, is frequently observed in both hereditary and sporadic colorectal cancer (CRC). It has been established that defects in the DNA mismatch repair (MMR) pathway underlie the development of MSI in CRC. After the inactivation of the DNA MMR pathway, misincorporations, insertions and deletions introduced by DNA polymerase slippage are not properly recognized and corrected. Specific genomic regions, including microsatellites, are more prone for DNA polymerase slippage and, therefore, more susceptible for the introduction of these mutations if the DNA MMR capacity is lost. Some of these susceptible genomic regions are located within the coding regions of genes. Insertions and deletions in these regions may alter their reading frame, potentially resulting in the transcription and translation of frameshift peptides with c-terminally altered amino acid sequences. These frameshift peptides are called neoantigens and are highly immunogenic, which explains the enhanced immunogenicity of MSI CRC. Neoantigens contribute to increased infiltration of tumor tissue with activated neoantigen-specific cytotoxic T lymphocytes, a hallmark of MSI tumors. Currently, neoantigen-based vaccination is being studied in a clinical trial for Lynch syndrome and in a trial for sporadic MSI CRC of advanced stage. In this Focussed Research Review, we summarize current knowledge on molecular mechanisms and address immunological features of tumors with MSI. Finally, we describe their implications for immunotherapeutic approaches and provide an outlook on next-generation immunotherapy involving neoantigens and combinatorial therapies in the setting of MSI CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.